Aldeyra (NASDAQ: ALDX) grants CEO 1.88M options and bonus units

(Neutral)

Form Type

Rhea-AI Filing Summary

Aldeyra Therapeutics, Inc. President and CEO Todd C. Brady received new equity-based compensation awards. He was granted a stock option covering 1,880,510 shares of common stock at an exercise price of $1.77 per share. This option vests in equal monthly installments over 48 months of continuous service after January 1, 2026 and expires on March 26, 2036.

Brady was also awarded 632,318 bonus units, which vest in equal annual installments over four years beginning on March 27, 2026, contingent on continued service. Each vested bonus unit entitles him to a cash payment equal to the closing price per share of Aldeyra’s common stock on the payment date, made on the earlier of four years from grant or a Change of Control. These are compensation grants, not open-market share purchases or sales.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Brady Todd C

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	1,880,510	$0.00	$0.00
Grant/Award	Bonus Units	632,318	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 1,880,510 shares (Direct); Bonus Units — 632,318 shares (Direct)

Footnotes (2)

F1. The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2026.
F2. The bonus units vest ratably in equal annual installments over a four-year period beginning on March 27, 2026, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date.

Key Figures

Stock options granted: 1,880,510 shares Option exercise price: $1.77 per share Option expiration: March 26, 2036 +3 more

6 metrics

Stock options granted 1,880,510 shares Option on common stock granted to CEO on March 27, 2026

Option exercise price $1.77 per share Conversion or exercise price of CEO stock option

Option expiration March 26, 2036 Expiration date of CEO stock option grant

Bonus units granted 632,318 units Cash-settled bonus units tied to common stock value

Option vesting period 48 months Monthly vesting over four years after January 1, 2026

Bonus unit vesting Four annual installments Annual vesting starting March 27, 2026, over four years

Key Terms

Stock Option (right to buy), Bonus Units, Change of Control, vesting, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Bonus Units financial

"security_title: Bonus Units"

Change of Control financial

"on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer"

A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.

vesting financial

"shall vest in equal monthly installments over the next 48 months of continuous service"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"conversion_or_exercise_price: 1.7700"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/31/2026 - 04:17 PM

FAQ

What did Aldeyra Therapeutics (ALDX) CEO receive in this Form 4 filing?

The CEO received a grant of stock options and bonus units as compensation. He was awarded options on 1,880,510 common shares at $1.77 per share and 632,318 bonus units that pay cash based on Aldeyra’s future stock price upon vesting.

Are there any open-market stock purchases or sales in Aldeyra (ALDX) CEO’s Form 4?

No, the Form 4 reflects compensation awards, not market trades. It reports grants of stock options and cash-settled bonus units, with no shares bought or sold in the open market by the CEO in this filing.

How do the Aldeyra (ALDX) CEO’s new stock options vest and when do they expire?

The options vest in equal monthly installments over 48 months of continuous service after January 1, 2026. They cover 1,880,510 common shares at a $1.77 exercise price and expire on March 26, 2036 if not exercised earlier.

What are the bonus units granted to Aldeyra (ALDX) CEO and how are they paid?

The CEO received 632,318 bonus units that vest in equal annual installments over four years from March 27, 2026. Each vested unit pays cash equal to Aldeyra’s common stock closing price on the payment date, triggered by four years from grant or a Change of Control.

What service conditions apply to Aldeyra (ALDX) CEO’s new equity awards?

Both awards require continued service to Aldeyra. The stock options vest monthly over 48 months after January 1, 2026, and the 632,318 bonus units vest annually over four years from March 27, 2026, assuming ongoing continuous service through each vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brady Todd C

(Last)

(First)

(Middle)

C/O ALDEYRA THERAPEUTICS, INC.

131 HARTWELL AVENUE

(Street)

LEXINGTON

MASSACHUSETTS

02421

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aldeyra Therapeutics, Inc. [ ALDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$1.77	03/27/2026		A		1,880,510		⁽¹⁾	03/26/2036	Common Stock	1,880,510	$0	1,880,510	D
Bonus Units	⁽²⁾	03/27/2026		A		632,318		⁽²⁾	⁽²⁾	Common Stock	632,318	$0	632,318	D

Explanation of Responses:

1. The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2026.

2. The bonus units vest ratably in equal annual installments over a four-year period beginning on March 27, 2026, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date.

	/s/ Todd C. Brady	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR